https://www.selleckchem.com/products/bi-2493.html
net.Sodium Glucose cotransporter-2 inhibitors (SGLT-2i) and Glucagon like peptide 1 receptor agonists (GLP1-RA) have revolutionised the approach for modern management of type 2 diabetes in view of their outcome altering abilities. An objective component of the primary endpoints used in the Cardiovascular Outcome Trials (CVOT) is cardiovascular (CV) death. However, the reason behind the decrease in CV deaths (compared to the placebo arm) appear to arise from divergent underlying processes. Recent meta-analysis of SGLT-2i and GLP1-RA indi
Like
Comment
Share
